Andy Jones

Articles

Pharma is moving towards greater patientcentricity – but there are plenty of obstacles and commercial pressures remaining, reports Andrew McConaghie.

News

Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.